“The temporary suspension of patents for anti-Covid vaccines would not allow a significant increase in production: the limiting factor is the availability of technology and all components of production. It is a complex process that must be managed by those with expertise and history”, says Pasquale Frega, president and CEO of Novartis Italia.
Patent suspension, the reasons for the no. Frega (Novartis): “Vaccine production would not increase”
He adds “Unlike drugs, vaccines are mostly administered to healthy people and the tolerance level on safety and quality must be maximum”
